<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04468611</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-17T04:17:15+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Efficacy of ivabradine in heart failure patients with a high‐risk profile (analysis from the SHIFT trial)</title>
            <author role="aut">
              <persName>
                <forename type="first">Amr</forename>
                <surname>Abdin</surname>
              </persName>
              <email type="md5">0d4865ab2e659087261903694d512ef8</email>
              <email type="domain">uks.eu</email>
              <idno type="idhal" notation="numeric">1354805</idno>
              <idno type="halauthorid" notation="string">2489285-1354805</idno>
              <idno type="ORCID">https://orcid.org/0000-0003-0847-1694</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Michel</forename>
                <surname>Komajda</surname>
              </persName>
              <idno type="halauthorid">744959-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Jeffrey</forename>
                <forename type="middle">S</forename>
                <surname>Borer</surname>
              </persName>
              <idno type="halauthorid">3061724-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Ian</forename>
                <surname>Ford</surname>
              </persName>
              <idno type="halauthorid">455364-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Luigi</forename>
                <surname>Tavazzi</surname>
              </persName>
              <idno type="halauthorid">703558-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Cécile</forename>
                <surname>Batailler</surname>
              </persName>
              <idno type="halauthorid">1213782-0</idno>
              <affiliation ref="#struct-300074"/>
              <affiliation ref="#struct-581164"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Karl</forename>
                <surname>Swedberg</surname>
              </persName>
              <idno type="halauthorid">1093858-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Giuseppe M.C.</forename>
                <surname>Rosano</surname>
              </persName>
              <idno type="halauthorid">2510663-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Felix</forename>
                <surname>Mahfoud</surname>
              </persName>
              <idno type="halauthorid">1334711-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Michael</forename>
                <surname>Böhm</surname>
              </persName>
              <idno type="halauthorid">576852-0</idno>
            </author>
            <editor role="depositor">
              <persName>
                <forename>François</forename>
                <surname>Bermond</surname>
              </persName>
              <email type="md5">a9ece7d6b660bc1db75ecff946dc8790</email>
              <email type="domain">univ-eiffel.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2024-02-20 14:53:31</date>
              <date type="whenModified">2025-07-25 03:35:45</date>
              <date type="whenReleased">2024-02-22 13:58:12</date>
              <date type="whenProduced">2023-07-10</date>
              <date type="whenEndEmbargoed">2024-02-20</date>
              <ref type="file" target="https://univ-lyon1.hal.science/hal-04468611v1/document">
                <date notBefore="2024-02-20"/>
              </ref>
              <ref type="file" subtype="greenPublisher" n="1" target="https://univ-lyon1.hal.science/hal-04468611v1/file/Abdin%20et%20al.%20-%202023%20-%20Efficacy%20of%20ivabradine%20in%20heart%20failure%20patients%20w.pdf" id="file-4468611-3876856">
                <date notBefore="2024-02-20"/>
              </ref>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="456622">
                <persName>
                  <forename>François</forename>
                  <surname>Bermond</surname>
                </persName>
                <email type="md5">a9ece7d6b660bc1db75ecff946dc8790</email>
                <email type="domain">univ-eiffel.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04468611</idno>
            <idno type="halUri">https://univ-lyon1.hal.science/hal-04468611</idno>
            <idno type="halBibtex">abdin:hal-04468611</idno>
            <idno type="halRefHtml">&lt;i&gt;ESC Heart Failure&lt;/i&gt;, 2023, 10 (5), pp.2895-2902. &lt;a target="_blank" href="https://dx.doi.org/10.1002/ehf2.14455"&gt;&amp;#x27E8;10.1002/ehf2.14455&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">ESC Heart Failure, 2023, 10 (5), pp.2895-2902. &amp;#x27E8;10.1002/ehf2.14455&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4468611-3876856"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="HCL">Hospices Civils de Lyon</idno>
            <idno type="stamp" n="UNIV-LYON1">Université Claude Bernard - Lyon I</idno>
            <idno type="stamp" n="IFSTTAR">Ifsttar</idno>
            <idno type="stamp" n="LBMC" corresp="UNIV-LYON1">Laboratoire de Biomécanique et Mécanique des Chocs</idno>
            <idno type="stamp" n="UDL">UDL</idno>
            <idno type="stamp" n="UNIV-LYON">Université de Lyon</idno>
            <idno type="stamp" n="UNIV-EIFFEL">Université Gustave Eiffel</idno>
            <idno type="stamp" n="U-EIFFEL">Université Gustave Eiffel</idno>
            <idno type="stamp" n="TS2">Transport, Santé, Sécurité</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Efficacy of ivabradine in heart failure patients with a high‐risk profile (analysis from the SHIFT trial)</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Amr</forename>
                    <surname>Abdin</surname>
                  </persName>
                  <email type="md5">0d4865ab2e659087261903694d512ef8</email>
                  <email type="domain">uks.eu</email>
                  <idno type="idhal" notation="numeric">1354805</idno>
                  <idno type="halauthorid" notation="string">2489285-1354805</idno>
                  <idno type="ORCID">https://orcid.org/0000-0003-0847-1694</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Michel</forename>
                    <surname>Komajda</surname>
                  </persName>
                  <idno type="halauthorid">744959-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Jeffrey</forename>
                    <forename type="middle">S</forename>
                    <surname>Borer</surname>
                  </persName>
                  <idno type="halauthorid">3061724-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Ian</forename>
                    <surname>Ford</surname>
                  </persName>
                  <idno type="halauthorid">455364-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Luigi</forename>
                    <surname>Tavazzi</surname>
                  </persName>
                  <idno type="halauthorid">703558-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Cécile</forename>
                    <surname>Batailler</surname>
                  </persName>
                  <idno type="halauthorid">1213782-0</idno>
                  <affiliation ref="#struct-300074"/>
                  <affiliation ref="#struct-581164"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Karl</forename>
                    <surname>Swedberg</surname>
                  </persName>
                  <idno type="halauthorid">1093858-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Giuseppe M.C.</forename>
                    <surname>Rosano</surname>
                  </persName>
                  <idno type="halauthorid">2510663-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Felix</forename>
                    <surname>Mahfoud</surname>
                  </persName>
                  <idno type="halauthorid">1334711-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Michael</forename>
                    <surname>Böhm</surname>
                  </persName>
                  <idno type="halauthorid">576852-0</idno>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">126094</idno>
                <idno type="eissn">2055-5822</idno>
                <title level="j">ESC Heart Failure</title>
                <imprint>
                  <publisher>Wiley</publisher>
                  <biblScope unit="volume">10</biblScope>
                  <biblScope unit="issue">5</biblScope>
                  <biblScope unit="pp">2895-2902</biblScope>
                  <date type="datePub">2023-07-10</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1002/ehf2.14455</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en">Heart rate</term>
                <term xml:lang="en">High risk</term>
                <term xml:lang="en">Risk indicators</term>
                <term xml:lang="en">Ivabradine</term>
                <term xml:lang="en">Heart failure</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv">Life Sciences [q-bio]</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Abstract Aims Early start and patient profile‐oriented heart failure (HF) management has been recommended. In this post hoc analysis from the SHIFT trial, we analysed the treatment effects of ivabradine in HF patients with systolic blood pressure (SBP) &lt; 110 mmHg, resting heart rate (RHR) ≥ 75 b.p.m., left ventricular ejection fraction (LVEF) ≤ 25%, New York Heart Association (NYHA) Class III/IV, and their combination. Methods and results The SHIFT trial enrolled 6505 patients (LVEF ≤ 35% and RHR ≥ 70 b.p.m.), randomized to ivabradine or placebo on the background of guideline‐defined standard care. Compared with placebo, ivabradine was associated with a similar relative risk reduction of the primary endpoint (cardiovascular death or HF hospitalization) in patients with SBP &lt; 110 and ≥110 mmHg [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.74–1.08 vs. HR 0.80, 95% CI 0.72–0.89, P interaction = 0.34], LVEF ≤ 25% and &gt;25% (HR 0.85, 95% CI 0.72–1.01 vs. HR 0.80, 95% CI 0.71–0.90, P interaction = 0.53), and NYHA III–IV and II (HR 0.83, 95% CI 0.74–0.94 vs. HR 0.81, 95% CI 0.69–0.94, P interaction = 0.79). The effect was more pronounced in patients with RHR ≥ 75 compared with &lt;75 (HR 0.76, 95% CI 0.68–0.85 vs. HR 0.97, 95% CI 0.81–0.1.16, P interaction = 0.02). When combining these profiling parameters, treatment with ivabradine was also associated with risk reductions comparable with patients with low‐risk profiles for the primary endpoint (relative risk reduction 29%), cardiovascular death (11%), HF death (49%), and HF hospitalization (38%; all P values for interaction: 0.40). No safety concerns were observed between study groups. Conclusions Our analysis shows that RHR reduction with ivabradine is effective and improves clinical outcomes in HF patients across various risk indicators such as low SBP, high RHR, low LVEF, and high NYHA class to a similar extent and without safety concern.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="regroupinstitution" xml:id="struct-300074" status="VALID">
          <idno type="IdRef">026534657</idno>
          <idno type="ROR">https://ror.org/01502ca60</idno>
          <orgName>Hospices Civils de Lyon</orgName>
          <orgName type="acronym">HCL</orgName>
          <desc>
            <address>
              <addrLine>3 Quai des Célestins69002 Lyon</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.chu-lyon.fr/fr/hospices-civils-de-lyon-hcl</ref>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-581164" status="VALID">
          <idno type="IdRef">15072411X</idno>
          <idno type="ISNI">0000000406234692</idno>
          <idno type="RNSR">200717404S</idno>
          <orgName>Laboratoire de Biomécanique et Mécanique des Chocs</orgName>
          <orgName type="acronym">LBMC UMR T9406</orgName>
          <date type="start">2020-01-01</date>
          <desc>
            <address>
              <addrLine>25, avenue François Mitterrand, Cité des mobilités F-69675 Bron Cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.lbmc.ifsttar.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-194495" type="direct"/>
            <relation active="#struct-301088" type="indirect"/>
            <relation name="UMR_T9406" active="#struct-580722" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-194495" status="VALID">
          <idno type="IdRef">026402823</idno>
          <idno type="ISNI">0000000121686185</idno>
          <idno type="ROR">https://ror.org/029brtt94</idno>
          <orgName>Université Claude Bernard Lyon 1</orgName>
          <orgName type="acronym">UCBL</orgName>
          <desc>
            <address>
              <addrLine>43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-lyon1.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-301088" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-301088" status="VALID">
          <idno type="ROR">https://ror.org/01rk35k63</idno>
          <orgName>Université de Lyon</orgName>
          <desc>
            <address>
              <addrLine>92 rue Pasteur - CS 30122, 69361 Lyon Cedex 07</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.universite-lyon.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-580722" status="VALID">
          <idno type="ROR">https://ror.org/03x42jk29</idno>
          <orgName>Université Gustave Eiffel</orgName>
          <date type="start">2020-01-01</date>
          <desc>
            <address>
              <addrLine>Cité Descartes, 5 Boulevard Descartes • Champs-sur-Marne, 77454 Marne-la-Vallée Cedex 2</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.univ-gustave-eiffel.fr/</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>